首頁 › 頭頸部鱗狀細胞癌 › 德克薩斯州 › Austin
Austin, TX 的 頭頸部鱗狀細胞癌 臨床試驗
8 項針對 頭頸部鱗狀細胞癌 的研究正在 Austin（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #46, Austin
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- Texas Oncology (Balcones) - SCRI, Austin
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
招募中1/2 期
- NEXT Oncology Austin, Austin
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- NEXT Oncology Austin /ID# 243005, Austin
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
招募中1 期
- NEXT Texas LLC - Austin, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
招募中1 期
- NEXT Oncology, Austin, TX 78758
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
招募中1 期
- Dren Investigational Site, Austin
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 135, Austin
其他城市的 頭頸部鱗狀細胞癌 試驗
- Houston, TX47 項研究
- Los Angeles, CA42 項研究
- Boston, MA40 項研究
- New York City, NY39 項研究
- Nashville, TN39 項研究
- St. Louis, MO28 項研究
- Arlington, VA26 項研究
- Philadelphia, PA26 項研究
- Chicago, IL26 項研究
- Atlanta, GA24 項研究
- San Antonio, TX22 項研究
- New Haven, CT22 項研究
Austin 的其他研究
- 非小細胞肺癌30 項研究
- 癌症（所有類型）20 項研究
- 肥胖症20 項研究
- 大腸直腸癌19 項研究
- 轉移性癌症19 項研究
- 過重18 項研究
- 心臟衰竭18 項研究
- 乳癌18 項研究
- 卵巢癌17 項研究
- 子宮內膜癌15 項研究
- 前列腺癌15 項研究
- 憂鬱症14 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。